Last reviewed · How we verify
Aplause®
Aplause is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune responses.
Aplause is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune responses. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | Aplause® |
|---|---|
| Sponsor | Phytopharm Consulting Brazil |
| Drug class | S1P receptor modulator |
| Target | S1PR1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By binding to S1PR1, Aplause reduces the number of lymphocytes in the blood and tissues, which can help to prevent or treat autoimmune diseases. This mechanism of action is thought to be responsible for the therapeutic effects of Aplause in conditions such as multiple sclerosis.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Headache
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aplause® CI brief — competitive landscape report
- Aplause® updates RSS · CI watch RSS
- Phytopharm Consulting Brazil portfolio CI